Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide in hepatic impairment
NCT06052566Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of efinopegdutide in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve From Time 0 to Infinity at 35 days, Area Under the Curve From Time 0 to Last Sampling Time at 35 days and 5 more. Started Nov 2023; status: completed.
02
Drugs
efinopegdutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06052566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052566.